Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

BIND Therapeutics Company Profile (NASDAQ:BIND)

Consensus Ratings for BIND Therapeutics (NASDAQ:BIND) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $11.50 (109.09% upside)

Analysts' Ratings History for BIND Therapeutics (NASDAQ:BIND)
Show:
DateFirmActionRatingPrice TargetDetailsShare
12/19/2014Stifel NicolausLower Price TargetBuy$20.00 -> $13.00ViewTweet This Rating  Share This Rating on StockTwits
12/4/2014Credit SuisseDowngradeOutperform -> Neutral$20.00 -> $10.00ViewTweet This Rating  Share This Rating on StockTwits
8/19/2014Stifel NicolausInitiated CoverageBuy$20.00ViewTweet This Rating  Share This Rating on StockTwits
7/3/2014Credit SuisseReiterated RatingOutperform$21.00 -> $20.00ViewTweet This Rating  Share This Rating on StockTwits
10/15/2013Cowen and CompanyInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
10/15/2013JMP SecuritiesInitiated CoverageOutperform$30.00ViewTweet This Rating  Share This Rating on StockTwits
10/15/2013Stifel NicolausInitiated CoverageBuy$20.00ViewTweet This Rating  Share This Rating on StockTwits
10/15/2013Credit SuisseInitiated CoverageOutperform$21.00ViewTweet This Rating  Share This Rating on StockTwits
(Data available from 12/20/2012 forward)